News

An advisory committee of the European Medicines Agency, or EMA — which evaluations medications for drug approval in the European Union — has recommended Uplizna (inebilizumab) for the treatment of adults with active IgG4-related disease (IgG4-RD). The positive opinion from the EMA’s Committee for Medicinal Products for Human…

People with immunoglobulin G4-related disease (IgG4-RD) are more likely to relapse if they have allergies, multiple organ involvement, or low levels of complement proteins — but using corticosteroid treatments together with immunosuppressants may reduce this risk. That’s according to a meta-analysis of 24 studies that sought to identify potential…

Rituximab is effective for all four clinical profiles of immunoglobulin G4-related disease (IgG4-RD), but two IgG4-RD profiles, or phenotypes, may show poorer responses, according to a multicenter study in Europe. “Patients in the retroperitoneal and aortic and head and neck-limited phenotypes may be less responsive,” the researchers said, and…

Zenas Biopharma has secured up to $300 million from Royalty Pharma to accelerate the development of obexelimab, its investigational treatment that could provide much-needed relief for people with immunoglobulin G4-related disease (IgG4-RD). In exchange, Royalty Pharma will receive a share of royalties on sales of obexelimab, which is…

Diagnosing IgG4-related disease (IgG4-RD) in children may require a flexible framework involving many kinds of tests, as the disease often looks different in children than in adults, according to a review study from researchers in Italy. While IgG4-RD in adults usually affects multiple organs over time, in children it…

The European Medicines Agency has granted orphan drug designation to Sanofi’s rilzabrutinib as a potential treatment for immunoglobulin G4-related disease (IgG4-RD), according to a company press release. Orphan drug status is meant to support the development of potential treatments for life-threatening or chronically debilitating rare diseases for which…

Zenas Biopharma said it expects top-line results from INDIGO, a Phase 3 clinical trial testing obexelimab in people with immunoglobulin G4-related disease (IgG4-RD), “around year-end.” We are very pleased with the rapid advancement of our broad obexelimab development program,” Lonnie Moulder, founder and CEO of Zenas, said…

Immunoglobulin G4-related disease (IgG4-RD) affecting the organs and tubes involved in storing and transporting the digestive fluid bile can be challenging to identify, but an early diagnosis — as well as prompt treatment — is “critical” to ensure optimal clinical outcomes. That’s according to the researchers behind a new…

Imaging of the salivary glands can help distinguish IgG4-related disease (IgG4-RD) from other disorders that can cause inflammation in those glands, a new study shows. The findings indicate people with salivary gland inflammation related to IgG4-RD tend to show distinctive patterns of damage to some of the tubes, or…

Type 1 autoimmune pancreatitis (AIP), a type of IgG4-related disease (IgG4-RD) involving the pancreas, can look different depending on the levels of immunoglobulin G4 (IgG4), a study found. People with normal IgG4 levels typically had more limited damage in the pancreas and some issues outside it, the researchers found.